Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 17 week, investigator-initiated, single-center, double-blind, randomized, placebo-controlled, cross-over trial of pregabalin in essential tremor

Next Previous
Trial Profile

A 17 week, investigator-initiated, single-center, double-blind, randomized, placebo-controlled, cross-over trial of pregabalin in essential tremor

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 16 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Essential tremor
  • Focus Therapeutic Use

Most Recent Events

  • 15 Oct 2009 Results published in the Journal of the Neurological Sciences.
  • 07 Jun 2009 Results presented at the 13th International Congress of Parkinson's Disease and Movement Disorders.
  • 07 Jun 2009 Primary endpoint 'Tremor Clinical Rating Scale' has not been met according to results presented at the 13th International Congress of Parkinson's Disease and Movement Disorders.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top